The expanded partnership solidifies the commercial strategy for bringing the HeartLight Endoscopic Ablation System to the Japanese market.
Company Receives Substantial Investment Under Expanded Agreement Terms |
| [09-January-2018] |
| MARLBOROUGH, Mass., Jan. 9, 2018 /PRNewswire/ -- CardioFocus Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced that it has entered into an expanded partnership with Japan Lifeline. The expanded partnership solidifies the commercial strategy for bringing the HeartLight® Endoscopic Ablation System to the Japanese market. To support Japanese approval, CardioFocus originally established a distribution partnership with JLL in 2014. Since receiving approval from the Japanese Ministry of Health, Labour and Welfare in July, initial commercial cases have been completed successfully at four hospitals. The companies expect full commercial launch of the HeartLight System to begin in 2018 after national reimbursement is in place. Under the expanded agreement, CardioFocus and JLL will increase the scope of their Japan commercialization efforts and pursue commercialization of the HeartLight System in other Asia Pacific markets. JLL is also making a substantial financial investment in CardioFocus that will be used to accelerate the market expansion of HeartLight globally and support development of the company’s third-generation product, the HeartLight X3 System, which will begin clinical evaluation in Europe during 2018 with prospects of a Japan launch in the future. The HeartLight System is a visually guided laser balloon technology for controlled and consistent pulmonary vein isolation (PVI) treatment of atrial fibrillation (AF). Its direct visualization, titratable laser energy, and universal balloon design make it a new standard for PVI procedures. It provides an effective and safe treatment option for patients whose heart arrhythmias are insufficiently controlled with medication. “In Japan, physicians are responding very positively to the HeartLight System,” said Keisuke Suzuki, president and chief executive officer of Japan Lifeline. “We are eager to continue the commercial launch and bring this revolutionary new treatment to more AF patients.” “We greatly value this partnership with JLL and the momentum it has created for the HeartLight System in Japan and look forward to offering it in additional Asia Pacific markets,” said Paul A. LaViolette, executive chairman of CardioFocus. “This expanded agreement will help CardioFocus achieve its long-term goals as a company committed to leading in the field of PVI.” About CardioFocus, Inc. About Japan Lifeline Co., Ltd. Media Contact: View original content with multimedia:http://www.prnewswire.com/news-releases/cardiofocus-announces-expanded-partnership-with-japan-lifeline-300579181.html SOURCE CardioFocus, Inc. | ||
Company Codes: Tokyo:7575 |
